C4 Therapeutics, INC 8-K filings

C4 Therapeutics announced second quarter 2026 financial results, highlighting progress in its cemsidomide clinical trials and a strong cash runway extending to the end of 2028.

C4 Therapeutics stockholders re-elected directors, ratified auditors, and approved an amendment to the 2020 Stock Option and Incentive Plan.

C4 Therapeutics announced positive Phase 1 data for cemsidomide, an IKZF1/3 degrader, showing a 53% overall response rate in heavily pretreated relapsed/refractory multiple myeloma patients.

C4 Therapeutics, Inc. announced that Mark Mossler will depart as Chief Accounting Officer, with CFO Kendra R. Adams assuming the role.

C4 Therapeutics announced first-quarter 2026 financial results, highlighting progress in its cemsidomide multiple myeloma trials and a new collaboration with Roche focused on degrader-antibody conjugates.

C4 Therapeutics, Inc. has amended its bylaws to designate specific U.S. District Courts as the exclusive forums for securities-related litigation.

C4 Therapeutics and Roche have entered into a new research collaboration and license agreement to discover, develop, and commercialize degrader-antibody conjugates (DACs) for oncology.

C4 Therapeutics reported strong Q4 and full year 2025 financial results, highlighted by significant clinical progress for cemsidomide and an extended cash runway to the end of 2028.

C4 Therapeutics outlines strategic milestones through 2028 for its lead drug cemsidomide and a new discovery strategy, backed by a cash runway extending to the end of 2028.

C4 Therapeutics reported Q3 2025 financial results, highlighted positive cemsidomide Phase 1 data in multiple myeloma, and secured $125 million in gross proceeds extending its cash runway to late 2028.

C4 Therapeutics, Inc. announced an underwritten offering of common stock and warrants, raising approximately $117.0 million in net proceeds to extend its cash runway through the end of 2028.

C4 Therapeutics, Inc. announced positive Phase 1 clinical trial data for cemsidomide in relapsed/refractory multiple myeloma and outlined an accelerated path to registration, while also terminating a sales agreement prospectus.

C4 Therapeutics announced a clinical trial collaboration and supply agreement with Pfizer Inc. to evaluate cemsidomide in combination with elranatamab for relapsed/refractory multiple myeloma.

C4 Therapeutics announced positive Phase 1 clinical trial data for cemsidomide in relapsed/refractory multiple myeloma, demonstrating a 50% overall response rate at the highest dose and a differentiated safety profile.

C4 Therapeutics reports Q2 2025 financial results, highlights positive cemsidomide Phase 1 data in multiple myeloma, and extends cash runway to mid-2027.

C4 Therapeutics, Inc. announced that its stockholders approved an amendment to increase the authorized common stock from 150 million to 300 million shares, alongside the election of Class II directors and other key proposals at its Annual Meeting on June 18, 2025.

C4 Therapeutics reports promising early clinical data for cemsidomide in multiple myeloma and provides a financial update for the first quarter of 2025.

Bruce Downey will retire from C4 Therapeutics' Board of Directors and not stand for reelection at the 2025 Annual Meeting of Stockholders.

C4 Therapeutics announces financial results for 2024 and provides updates on its clinical programs, including cemsidomide and CFT1946, with plans to initiate new clinical trials in early 2026.

C4 Therapeutics anticipates key data readouts and clinical trial advancements across its degrader medicine portfolio in 2025, with cash runway extending into 2027.

C4 Therapeutics announced positive clinical trial updates for cemsidomide, showcasing its potential as a best-in-class IKZF1/3 degrader in both multiple myeloma and non-Hodgkin's lymphoma.

C4 Therapeutics has appointed Steve Hoerter, a seasoned oncology executive, to its Board of Directors to guide the company's pipeline progress.

C4 Therapeutics announced its third quarter 2024 financial results, highlighting clinical trial advancements and a strong cash position.

C4 Therapeutics has appointed Paige Mahaney as its new Chief Scientific Officer, succeeding Stewart Fisher who is retiring but will remain as a consultant.

C4 Therapeutics has appointed Paige Mahaney as its new Chief Scientific Officer, effective October 28, 2024, following the retirement of Stewart Fisher.

C4 Therapeutics has amended its 2020 Stock Option and Incentive Plan to require shareholder approval for any future reductions in stock option exercise prices or repricings.

C4 Therapeutics has appointed Stephen Fawell, a veteran biotechnology leader, to its Board of Directors, while Malcolm Salter retires after nearly a decade of service.

C4 Therapeutics announced its second quarter 2024 financial results, highlighted by increased revenue and advancements in its clinical programs, including upcoming presentations at the ESMO Congress.

C4 Therapeutics held its annual meeting on June 20, 2024, where stockholders elected three Class I directors, approved executive compensation in an advisory vote, and ratified KPMG LLP as the company's auditor for the fiscal year ending December 31, 2024.

C4 Therapeutics has appointed Ron Cooper as Chairman of the Board, succeeding Bruce Downey, as part of a strategic board evolution.